Emcure Pharmaceuticals Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹37,584 Cr
- Book Value
- ₹261
- Stock P/E
- 39.7
- Dividend Yield
- 0.15%
- ROE
- 20.1%
- ROCE
- 24.0%
- PEG Ratio
- 2.26
- EV/EBITDA
- 20.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Emcure Pharmaceuticals share price today
Emcure Pharmaceuticals (NSE: EMCURE) built its franchise where Indian pharma is stickiest: gynaecology, where it ranks at the top of the therapy, plus HIV antivirals, blood-related therapies and cardiology. These are prescription categories with real brand gravity — a gynaecologist’s habit is a decades-long revenue stream — supported by a differentiated injectables and biologics capability most mid-cap peers lack.
Post its 2024 IPO, the balance-sheet story is deleveraging (D/E 0.31 and falling) while Europe grows into the second engine. At 39.7× with 24% ROCE, our universe tags it wait: a franchise being repriced upward as debt melts, but not yet at a price that forgives missteps.
Domestic depth, European breadth
The domestic playbook is therapy leadership — being #1 where doctors are most loyal beats being #10 everywhere. Internationally, Emcure sidestepped the crowded US generics grave and built Europe and emerging markets instead, where pricing is saner and its injectables portfolio differentiates. The 17.5% five-year profit CAGR has been accelerating as IPO proceeds cut interest costs.
Watch-items: the D/E glidepath (0.31 is the highest on our mid-cap list), gynae franchise defence as biosimilars and trade generics probe it, Europe execution, and residual promoter-family holdings post-listing.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹37,584 Cr |
| P/E (TTM) | 39.7 |
| EV/EBITDA | 20.8 |
| Operating margin | 20.3% |
| ROE / ROCE | 20.1% / 24.0% |
| Debt to equity | 0.31 |
| Sales CAGR (5y) | 12.8% |
| Profit CAGR (5y) | 17.6% |
| Promoter holding | 77.8% |
| EPS (TTM) | ₹49.78 |
Emcure Pharmaceuticals share price target 2026 to 2030
EPS base ₹49.78 (TTM). Bear: domestic growth slows and Europe stalls — 8% growth, multiple at 24×. Base: deleveraging plus therapy leadership compound — 14% growth at 32×. Bull: Europe scales and margins expand debt-free — 18% growth at 40×.
| Year | Bear (24×, +8%) | Base (32×, +14%) | Bull (40×, +18%) |
|---|---|---|---|
| 2026 | ₹1,290 | ₹1,815 | ₹2,350 |
| 2027 | ₹1,395 | ₹2,070 | ₹2,775 |
| 2028 | ₹1,505 | ₹2,360 | ₹3,270 |
| 2029 | ₹1,625 | ₹2,690 | ₹3,860 |
| 2030 | ₹1,755 | ₹3,065 | ₹4,555 |
From ₹1,978, the base case is ≈ +55% over four and a half years. The bear case is −11% — branded-domestic franchises with falling debt rarely crater; they drift while earnings catch up. The range below is where the drift becomes the gift.
Reasons to own Emcure (at the right price)
- Gynaecology leadership — the stickiest prescription franchise in Indian pharma.
- Injectables/biologics capability that differentiates it from oral-solid crowds.
- Deleveraging is a built-in earnings accelerator: every rupee of debt repaid is margin.
- Europe-first international strategy avoids the US generics meat grinder.
- 24% ROCE improving as the balance sheet cleans.
The risks: D/E 0.31 is still the heaviest on our mid-cap pharma list, therapy concentration cuts both ways, and a 40× multiple already prepays a chunk of the deleveraging story.
Should you buy at the current price?
The live buy range below is for members — the entry that keeps the re-rating for you.
FAQ
What is the Emcure share price target for 2030? Base case ≈ ₹3,065 (32× on 14% compounded growth), bear ≈ ₹1,755, bull ≈ ₹4,555. Arithmetic above.
What is Emcure known for? Gynaecology leadership in India, plus HIV antivirals and blood therapeutics — brand-led domestic franchises with injectables manufacturing depth.
Why does the debt matter so much? Because it is the earnings lever: interest saved converts straight to profit, which is why profit growth has outrun sales growth since listing — and should continue while D/E glides down.
When are Emcure’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.